Clinical assessment in the spondyloarthropathies, including psoriatic arthritis

Current Opinion in Rheumatology

Volumn 18, Issue 4, 2006, Pages 354-358

  Van Den Bosch, Filip ^a   Cryssen, Bert Vander ^a   Mielants, Herman ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Ankylosing spondylitis; Assessment tools; Psoriatic arthritis; Spondyloarthropathy

Indexed keywords

ANKYLOSING SPONDYLITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; DACTYLITIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENTHESITIS; FEASIBILITY STUDY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RELIABILITY; REVIEW; SPONDYLOARTHROPATHY; SWELLING; VALIDATION PROCESS;

ARTHRITIS, PSORIATIC; HUMANS; SPONDYLARTHRITIS;

EID: 33748057128     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000231902.27419.64     Document Type: Review

References (32)

1. Dougados M, van der Linden S, Juhlin R, et al. The European spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34:1218-1227.
2. Kavanaugh A, Cassell S. Outcome measures in psoriatic arthritis. Curr Rheumatol Rep 2005; 7:195-200.
3. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21:2286-2291.
4. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21:2281-2285.
5. Dougados M, Gueguen A, Nakache JP, et al. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1988; 15:302-307.
6. Spoorenberg A, van der Heijde DMFM, de Klerk E, et al. A comparative study of the usefulness of the BASFI and the DFI in the assessment of AS. J Rheumatol 1999; 26:961-965.
7. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994; 21:1694-1698.
8. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65:316-320. An update on the assessment of efficacy of TNF blocking agents in patients with AS in daily practice.
9. Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 2005; 32:80-85. A new way of describing improvement.
10. Van der Heijde D, Bellamy N, Calin A, et al. Preliminary core sets for endpoints in ankylosing spondylitis. J Rheumatol 1997; 24:2225-2229.
11. Van der Heijde D, Calin A, Dougados M, et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy and clinical record keeping in AS: progress report of the ASAS Working Group. J Rheumatol 1999; 26:951-954.
12. Jones SD, Porter J, Garrett SL, et al. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 1995; 22:1609.
13. van der Heijde D, Landewé R, Feldtkeller E. Bath Ankylosing Spondylitis Metrology Index (BASMI): 3-point and 11-point answering scales are not interchangeable. Arthritis Rheum 2005; 52 (9 Suppl):S635.
14. Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNFa treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63:1438-1444.
15. Kruithof E, Van den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61:207-212.
16. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 2002; 41:1280-1285.
17. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2013-2020.
18. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727-735.
19. Fransen J, van Riel PL. Are better endpoints and better design of clinical trials needed? Best Pract Res Clin Rheumatol 2004; 18:97-109.
20. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64:1294-1298.
21. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20:579-581.
22. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44-48.
23. Choy EHS, Burmester GR, Bombardieri S, et al. Efficacy of adalimumab in psoriatic arthritis as measured by the disease activity score 28. Arthritis Rheum 2005; 52 (9 Suppl):S214.
24. Mander M, Simpson JM, McLellan A, et al. Studies with an enthesitis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987; 46:197-202.
25. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62:127-132.
26. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002; 359:1187-1193.
27. Gladman D, Cook RJ, Schentag C, et al. The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. J Rheumatol 2004; 31:1126-1131.
28. Brockbank J, Stein M, Schentag C, Gladman DD. Characteristics of dactylitis in psoriatic arthritis. J Rheumatol 2001; 28 (Suppl 6):1416.
29. Mease P, Kivitz A, Burch F, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum 2004; 50:2264-2272.
30. Antoni C, Kavanaugh A, Kirkham B, et al. Sustained benefits of Infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) Arthritis Rheum 2005; 52:1227-1236.
31. Mease PJ, Gladman DD, Ritchlin CT, et al. for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:3279-3289.
32. Nash P, Mease PJ, Braun J, van der Heijde D. Seronegative spondyloarthropathies: to lump or split? Ann Rheum Dis 2005; 64 (Suppl II):ii9-ii13.